Novavax Secures $30 Million in Licensing Deal with Pfizer
Novavax and Pfizer have reached a licensing agreement for the Matrix-M adjuvant, providing Novavax with an immediate $30 million and potential future payments.
Insights:
Novavax Inc announced on January 20, 2026, that it has entered into a significant licensing agreement with Pfizer Inc for the use of its Matrix-M adjuvant technology. This deal, which grants Pfizer control over the development, manufacture, and commercialization of products containing the adjuvant, provides Novavax with an immediate $30 million upfront payment in the first quarter of 2026. Additionally, Novavax could receive up to $500 million in milestone payments as part of the agreement.
